William Ackman

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured moment to daydream about weekend plans. Our agenda is quite modest. We hope to clear some leaves from the campus, visit with the Pharmalot ancestors and do some writing. And what about you? Once again, we remind you this is a lovely time of year to enjoy the great outdoors. You could also make plans for a winter get-away or simply take stock. The possibilities are endless. Well, whatever you do, have a grand time, but be safe. See you soon…

There is rising uncertainty about J. Michael Pearson’s tenure as chief executive of Valeant Pharmaceuticals after hedge fund investor Bill Ackman expressed doubts publicly; Faced with nationwide rebukes and attacks from presidential candidates over drug prices, the PhRMA trade group is confronting a public storm unlike any in years; A Food and Drug Administration advisory panel overwhelmingly called for heightened label warnings on widely prescribed antibiotics called fluoroquinolones; and Sanofi chief executive officer Olivier Brandicourt plans to put some assets such as the animal health and European generics units under review, and cut costs by $1.63 billion.